Literature DB >> 8841950

Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.

W Walther1, U Stein.   

Abstract

Gene therapy is used to correct genetic defects or to deliver new therapeutic functions to the target cells. Viral vectors are employed mainly as a gene delivery system. A great variety of viral expression systems have been developed and assessed for their ability to transfer genes into somatic cells. In particular, retroviral and adenoviral mediated gene transfer have been extensively studied and improved. Preclinical and clinical studies covering a large range of genetic disorders are currently underway to solve basic issues dealing with gene transfer efficiencies, regulation of gene expression, and potential risks of the use of viral vectors. The majority of clinical gene therapy trials that employ viral vectors perform exvivo gene transfer into target cells. The main issue in potential clinical application of gene therapy is the need for increased gene transfer efficiency and target specificity associated with regulated gene expression at therapeutically relevant levels in vivo. Gene regulatory elements, such as promoters and enhancers, possess cell type specific activities and can be activated by certain induction factors (e.g., hormones, growth factors, cytokines, cytostatics, irradiation, heat shock) via responsive elements. A controlled and restricted expression of these genes can be achieved using such regulatory elements as internal promoters to drive the expression of therapeutic genes in viral vector constructs. In addition to high level and efficient gene expression, minimizing or excluding inappropriate gene expression in surrounding nontarget cells is of great importance for numerous gene therapeutic approaches. This contribution furnishes insight into the field of cell type specific promoter and enhancer systems which have been used for targeted and inducible expression of therapeutic genes in certain genetic disorders, viral infections, and malignancies. We also discuss promoters that represent attractive candidates for the construction of viral vectors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841950     DOI: 10.1007/bf00210632

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  79 in total

1.  Molecular cloning and characterization of the promoter region of the calcineurin A alpha gene.

Authors:  C D Chang; T Takeda; H Mukai; H Shuntoh; T Kuno; C Tanaka
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

Review 2.  Factors controlling the expression of mouse mammary tumour virus.

Authors:  W H Günzburg; B Salmons
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

3.  Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection.

Authors:  K P Ponder; R P Dunbar; D R Wilson; G J Darlington; S L Woo
Journal:  Hum Gene Ther       Date:  1991       Impact factor: 5.695

4.  Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase.

Authors:  M Hatzoglou; W Lamers; F Bosch; A Wynshaw-Boris; D W Clapp; R W Hanson
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

5.  Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression.

Authors:  H Schrewe; J Thompson; M Bona; L J Hefta; A Maruya; M Hassauer; J E Shively; S von Kleist; W Zimmermann
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

6.  Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus.

Authors:  G L Buchschacher; E O Freed; A T Panganiban
Journal:  Hum Gene Ther       Date:  1992-08       Impact factor: 5.695

7.  Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo.

Authors:  M G Dunckley; D J Wells; F S Walsh; G Dickson
Journal:  Hum Mol Genet       Date:  1993-06       Impact factor: 6.150

8.  Gene therapy for cancer using tumour-specific prodrug activation.

Authors:  J D Harris; A A Gutierrez; H C Hurst; K Sikora; N R Lemoine
Journal:  Gene Ther       Date:  1994-05       Impact factor: 5.250

9.  Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer.

Authors:  T Ferkol; G L Lindberg; J Chen; J C Perales; D R Crawford; O D Ratnoff; R W Hanson
Journal:  FASEB J       Date:  1993-08       Impact factor: 5.191

10.  Position-independent, high-level expression of the human beta-globin gene in transgenic mice.

Authors:  F Grosveld; G B van Assendelft; D R Greaves; G Kollias
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

View more
  11 in total

Review 1.  Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.

Authors:  Ethlinn V B van Gaal; Wim E Hennink; Daan J A Crommelin; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

2.  Cell targeting in anti-cancer gene therapy.

Authors:  Mohd Azmi Mohd Lila; John Shia Kwong Siew; Hayati Zakaria; Suria Mohd Saad; Lim Shen Ni; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2004-01

Review 3.  CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.

Authors:  Vera Paschon; Felipe Fernandes Correia; Beatriz Cintra Morena; Victor Allisson da Silva; Gustavo Bispo Dos Santos; Maria Cristina Carlan da Silva; Alexandre Fogaça Cristante; Stephanie Michelle Willerth; Florence Evelyne Perrin; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2020-01-11       Impact factor: 5.590

Review 4.  DNA-based therapeutics and DNA delivery systems: a comprehensive review.

Authors:  Siddhesh D Patil; David G Rhodes; Diane J Burgess
Journal:  AAPS J       Date:  2005-04-08       Impact factor: 4.009

5.  A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine.

Authors:  Charlie Yu Ming Hsu; Hasan Uludağ
Journal:  Nat Protoc       Date:  2012-04-19       Impact factor: 13.491

Review 6.  Gene and cell therapy for heart failure.

Authors:  Ebo D de Muinck
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 7.  Viral vectors for gene transfer: a review of their use in the treatment of human diseases.

Authors:  W Walther; U Stein
Journal:  Drugs       Date:  2000-08       Impact factor: 11.431

Review 8.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

9.  In vivo Antitumor Effect of an HPV-specific Promoter driving IL-12 Expression in an HPV 16-positive Murine Model of Cervical Cancer.

Authors:  Victor Hugo Bermúdez-Morales; Geny Fierros-Zarate; Celina García-Meléndrez; Juan Manuel Alcocer-Gonzalez; Ausencio Morales-Ortega; Oscar Peralta-Zaragoza; Kirvis Torres-Poveda; Ana Isabel Burguete-García; Eva Hernández-Márquez; Vicente Madrid-Marina
Journal:  J Cancer       Date:  2016-09-27       Impact factor: 4.207

10.  Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins.

Authors:  Jooyoung Lee; Haiwei Mou; Raed Ibraheim; Shun-Qing Liang; Pengpeng Liu; Wen Xue; Erik J Sontheimer
Journal:  RNA       Date:  2019-08-22       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.